Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors.
about
Cell Therapy in Patients with Critical Limb IschemiaPeripheral stem cell collection: from leukocyte growth factor to removal of catheter.Contribution of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) use in current cancer treatment: review of clinical data.Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation.Ofatumumab, a human anti-CD20 monoclonal antibody.Allogeneic hematopoietic stem cell donation-standardized assessment of donor outcome data: a consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT).Variant rs1801157 in the 3'UTR of SDF-1ß does not explain variability of healthy-donor G-CSF responsivenessThe evaluation of thioridazine as a hematopoietic progenitor cell mobilizing agent in healthy human subjectsEffects of granulocyte-colony-stimulating factor on Monosomy 7 aneuploidy in healthy hematopoietic stem cell and granulocyte donors.Biosimilar granulocyte-colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid?The colony-stimulating factors and cancer.Screening of related donors and peripheral blood stem cell collection practices at different Italian apheresis centres.Significant Improvements in the Practice Patterns of Adult Related Donor Care in US Transplantation Centers.Recommendations for managing the donation of haematopoietic stem cells from related and unrelated donors for allogeneic transplantation.Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Recovery of Unrelated Donors of Bone Marrow: A Prespecified Analysis from the Phase III Blood and Marrow Transplant Clinical Trials Network Protocol 0201Hematopoietic stem cell mobilization: updated conceptual renditionsMobilization of hematopoietic stem/progenitor cells: general principles and molecular mechanisms.G-CSF in Healthy Allogeneic Stem Cell Donors.Efficacy and side effects of granulocyte collection in healthy donors.Granulocyte colony-stimulating factor produces long-term changes in gene and microRNA expression profiles in CD34+ cells from healthy donors.Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers-results of a dose escalation trial.Colony-stimulating factors for febrile neutropenia during cancer therapy.Health-related quality of life of bone marrow versus peripheral blood stem cell donors: a prespecified subgroup analysis from a phase III RCT-BMTCTN protocol 0201.How we approach patient evaluation for hematopoietic stem cell transplantation.Mobilization of hematopoietic stem cells into the peripheral blood.Lenograstim: a review of its use in chemotherapy-induced neutropenia, for acceleration of neutrophil recovery following haematopoietic stem cell transplantation and in peripheral blood stem cell mobilization.Long-term safety of granulocyte colony-stimulating factor in normal donors: is it all clear?Hematopoietic stem cell donation.A review of the haematopoietic stem cell donation experience: is there room for improvement?Stem cell therapy in autoimmune rheumatic diseases: a comprehensive review.A review of the genetic and long-term effects of G-CSF injections in healthy donors: a reassuring lack of evidence for the development of haematological malignancies.G-CSF-primed BM for allogeneic SCT: revisited.Donors' health state the year after peripheral haematopoietic progenitor cell collection: A prospective follow-up study in related and unrelated donors compared to first-time platelet donors.Female donors and donors who are lighter than their recipient are less likely to meet the CD34+ cell dose requested for peripheral blood stem cell transplantation.Healthy donor hematopoietic stem cell mobilization with biosimilar granulocyte-colony-stimulating factor: safety, efficacy, and graft performance.Remobilization of hematopoietic stem cells in healthy donors for allogeneic transplantation.Collection of peripheral blood progenitor cells on Day 4 is feasible and effective while reducing granulocyte-colony-stimulating factor exposure to healthy donors.Eighteen years experience of granulocyte donations-acceptable donor safety?We have a specific duty to maximise the safety of related donorsConcerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association.
P2860
Q26795443-14F97323-2FEB-4BED-B50C-C13096AAF0EAQ30458178-3E81F88E-6359-4A51-BCDA-8AC4FCE45B5FQ33539387-EB92020E-35D1-4024-82ED-80E8CF4C38C5Q33718833-6E01741C-35A7-49AD-B711-C70148307524Q34095311-29B23426-966F-47C7-87B1-F5170D54984AQ34330585-9DEF14AF-A4D1-4A04-B2D3-73C8FD90F79CQ35213695-F237D231-62FB-42D0-B471-404C80F016B8Q35570535-32F559D3-D5BE-4B99-BA1E-F4490343FAD7Q35605853-5452317A-D929-48AB-B34B-A0FB64F18E7CQ35835005-14B7D7E0-01AA-4DB8-9FF0-C5C634DC21AAQ35936937-D7A71E58-CA6D-4D84-88BF-B7933A2EDEBAQ36393487-6954BE33-5858-4624-9C9D-70B0F2E18ABBQ36598360-231A18C0-766E-4958-BEBA-9DAA9D99DDF9Q36766486-9ACC7E78-2E16-47E0-96D2-362E4E65361CQ36902128-559CC52B-4B01-44FF-A135-9C130E87BAE9Q36912472-1DF5028F-B93C-4243-B05F-FDDB1D5769E2Q36912497-C29BEE8C-E43E-42CA-BEF1-1D43A404AD6BQ37180718-0F1E6475-CD34-4696-8EBC-8929AE639C65Q37180865-4DD3353E-2051-4E7F-9062-05A8DD322CD7Q37552014-421A8CE9-CF68-49E4-B152-B11244F8231DQ37554951-872A5C6D-74BD-4D3A-B416-33361800ABD5Q37626772-78B2F566-F64E-4D85-95C6-173E7D7FAAF1Q37689999-04BA6412-DCF6-417D-BF84-B9BFFE038500Q37755957-CA0C6761-DCED-43F5-996F-E2F640A14E6EQ37810088-FDC73990-FE1F-49A1-9763-2C2E46F02005Q37866758-8EE5EEBB-E390-49D7-94F2-CE316CC79ED0Q37996560-548F7531-0124-4C36-8DEB-F6186BDD647BQ38082689-15B44673-2DD5-4FA4-9A0D-80DB19FE8841Q38181958-9E766794-5ACE-4798-91EF-192CEC10809AQ38242079-8C958E84-E58E-4E73-9672-ED128DAACD33Q38323097-EE75BD4A-BD0E-414C-9FB5-EEF5062D7066Q38366631-40812240-E3B9-4293-A4DF-7E48529E04CDQ38712374-99D98A4F-DDE1-4E82-B1E4-14450728B7F2Q39186228-19180ED2-49C5-4A21-BAAA-27BB0D7FD981Q39385304-6C671E22-5426-4D93-8B0B-274044B44793Q39677517-7A8B5E54-FC82-4CDD-A3CA-8D5F69A854EFQ41485866-AF496F2D-67CD-4416-8EB8-B57BC3C11989Q41577983-0831F7B7-419D-4C13-A2D9-1DF17975C433Q42343632-023CE418-E662-4473-B012-7C43F7B37807Q42783305-0605348A-86DD-4FDB-8B2F-846B6B447210
P2860
Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Safety and efficacy of hematop ...... ter experience in 3928 donors.
@en
Safety and efficacy of hematop ...... ter experience in 3928 donors.
@nl
type
label
Safety and efficacy of hematop ...... ter experience in 3928 donors.
@en
Safety and efficacy of hematop ...... ter experience in 3928 donors.
@nl
prefLabel
Safety and efficacy of hematop ...... ter experience in 3928 donors.
@en
Safety and efficacy of hematop ...... ter experience in 3928 donors.
@nl
P2093
P1433
P1476
Safety and efficacy of hematop ...... ter experience in 3928 donors.
@en
P2093
Alexander H Schmidt
Claudia Rutt
Frank Kroschinsky
Kristina Hölig
Michael Kramer
Thilo Mengling
P304
P356
10.1182/BLOOD-2009-04-218651
P407
P577
2009-08-07T00:00:00Z